Dergiler / Annals of Medical Research / 2018 / Cilt: 25 - Sayı: 3

May ischemia modified albumin be a predictor in diagnosis of contrast induced nephropathy?

Sayfa
318–322
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further investigations will clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: “Ischemia modified albumin” (IMA) was investigated as a possible biomarker in several diseases such as vascular disorders.
📊
Temel Bulgular & Veri:We aimed to reveal the possible value of IMA in predicting the development of contrast induced nephropathy (CIN) after coronary angiography in patients with stable angina pectoris.Material and Methods: 106 patients underwent coronary angiography with a diagnosis of stable angina pectoris were included in our study.
💡
Sonuç & Katkı:Further investigations will clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: “Ischemia modified albumin” (IMA) was investigated as a possible biomarker in several diseases such as vascular disorders. We aimed to reveal the possible value of IMA in predicting the development of contrast induced nephropathy (CIN) after coronary angiography in patients with stable angina pectoris.Material and Methods: 106 patients underwent coronary angiography with a diagnosis of stable angina pectoris were included in our study. Basic demographic and clinical findings and laboratory values were recorded and analyzed. Serum creatinine (SCre) levels were also measured 48 hours after coronary angiography and recorded. Amount of contrast agent (CA) given during coronary angiography was recorded. The patients were divided into 2 groups: CIN positive and CIN negative groups.Results: CIN was developed in 14 patients (13%); and IMA levels were similar in CIN positive and negative groups (p>0.05). SCre (both measurements before and after CA administration) was not correlated with IMA levels. There was no association between drug usage and development of CIN (p>0.05). Comorbidities were not associated with the development of CIN (p>0.05) with the exception of hypertension (HT). Presence of hypertension (p=0.0393) and female gender (p=0.0199) was associated with development of CIN. Mean age was 61.3 and 52.3 in CIN positive and negative groups, respectively (p>0.05).Conclusion: Any specific biomarker indicating CIN is not available yet. Most frequently used marker is the measurement of SCre 24- 48 hours after administration of CA. We found IMA levels not to be a predictor for the development of CIN. Further investigations will clearly determine the importance of IMA as a biomarker in renal failure developed after CA administration.

🔖

Bu Makaleye Atıf Yap

AKAR, H., DUMAN, C., KURTULMUŞ, Y., EKİNCİ, F., TURKON, H., TOPALOĞLU, Ö., DEMİR, B., UZUN, M., TANRISEV, M. (2022). May ischemia modified albumin be a predictor in diagnosis of contrast induced nephropathy?. Annals of Medical Research, Cilt: 25 - Sayı: 3, 318–322. https://ajindex.com/articles/447418

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15(1):18-22.
  2. Cochran ST, Wong WS, Roe DJ. Predicting angiography induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol 1983;141(5):1027-33.
  3. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast induced nephropathy after percutaneous coronary interventions in relation to48 chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95(1):13-9.
  4. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999;51(5):521-6.
  5. Bilgi M, Keser A, Katlandur H, Sahin E, Kalkan AO, Yildiz M, Evaluation of the relationship between microalbuminuria and urine ischemia-modified albumin levels in patients with diabetic nephropathy. J Clin Lab Anal 2017;31(3). Ahmad A, Manjrekar P, Yadav C, Agarwal A, Srikantiah RM, Hegde A. Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy. Biomark Insights 2016;2;11:63-8.
  6. Molitoris BA, Dahl R, Geerdes A. Cytoskeleton disruption and apical redistribution of proximal tubule Na(+)-K(+)-ATPase during ischemia. Am J Physiol 1992;263(3 Pt 2):F488-95. Haller C, Kubler W. Contrast medium induced nephropathy:pathogenesis, clinical aspects, prevention. Dtsch Med Wochenschr 1999;124(11):332-6. Erley CM. Nephrotoxicity: focusing on radiocontrast nephropathy. Nephrol Dial Transplant 1999;14:13-5.
  7. Bhagavan NV, Lai EM, Rios P, Yang J, Ortega-Lopez AM, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003;49(4):581-5.
  8. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001;47(3):464-70.
  9. H Karaoğlan, M Öncel, S İpekçi, A Kıyıcı, Z Cansever Yeni tanı tip 2 diyabette iskemi modifiye albümin düzeyleri. Tıp Araştırmaları Dergisi 2016:14(1):1-5.
  10. Han K, Jia N, Yang L, Min LQ. Correlation between ischemiamodified albumin and lipid levels in patients with acute cerebrovascular disease. Mol Med Rep 2012;6(3):621-4.
  11. Kaya Z, Kayrak M, Gul EE,